Hong Kong Transportation Stock News

SEHK:1428
SEHK:1428Capital Markets

A Look At Bright Smart Securities (SEHK:1428) Valuation As Index Inclusion And Stock Connect Eligibility Approach

Bright Smart Securities & Commodities Group (SEHK:1428) is set to join the Hang Seng Composite Index, with the change effective March 9, 2026. This inclusion also paves the way for Shanghai Hong Kong Stock Connect eligibility. See our latest analysis for Bright Smart Securities & Commodities Group. The upcoming index inclusion sits on top of a strong run, with a 90 day share price return of 25% and a 1 year total shareholder return of 247.33% pointing to building momentum rather than fading...
SEHK:2517
SEHK:2517Consumer Retailing

A Look At Guoquan Food (Shanghai) (SEHK:2517) Valuation As It Expands Into Alcohol Beverage Partnerships

Alcohol partnership with Songhe puts Guoquan Food’s beverage plans in focus Guoquan Food (Shanghai) (SEHK:2517) has signed an alcoholic beverage procurement agreement with Songhe Group, tying drinks more tightly to its hot pot and barbecue offerings across more than 11,000 retail stores. See our latest analysis for Guoquan Food (Shanghai). The new alcohol deal lands after a strong 1 year total shareholder return of 119.77%, even though recent momentum has softened. The 7 day share price...
SEHK:2616
SEHK:2616Biotechs

CStone Pharmaceuticals (SEHK:2616) Valuation After FDA Clearance For Phase II Immunotherapy Trial

FDA clearance puts CS2009 in focus for CStone investors CStone Pharmaceuticals (SEHK:2616) said the U.S. FDA has cleared its IND for a Phase II trial of immunotherapy candidate CS2009 in advanced solid tumors, expanding an ongoing global multicenter study. See our latest analysis for CStone Pharmaceuticals. The FDA clearance comes as CStone’s share price sits at HK$5.91, with a 7 day share price return of 14.98% and a 1 year total shareholder return of 113.36%. This suggests momentum has...
SEHK:2005
SEHK:2005Pharmaceuticals

A Look At SSY Group’s Valuation After 2025 Profit Guidance Signals A Sharp Earnings Drop

SSY Group (SEHK:2005) has issued preliminary 2025 earnings guidance, telling investors to expect a 45% to 60% reduction in profit attributable to equity shareholders compared with the HK$1,061,150,000 reported for 2024. See our latest analysis for SSY Group. At a share price of HK$3.02, SSY Group has a modest 1-day share price return of a 0.33% decline, while its year-to-date share price return of 5.59% contrasts with a 3-year total shareholder return of a 28.75% decline. This suggests that...
SEHK:867
SEHK:867Pharmaceuticals

Assessing China Medical System Holdings (SEHK:867) Valuation After New Kidney Trial Approval And AI Drug Discovery Deal

China Medical System Holdings (SEHK:867) has drawn fresh attention after Chinese regulators cleared human trials for its CMS-D017 kidney disease therapy, alongside a new AI-focused drug discovery partnership with Insilico Medicine. See our latest analysis for China Medical System Holdings. The recent CMS D017 trial clearance and AI drug discovery tie up come as China Medical System Holdings’ share price sits at HK$15.33, with a 30 day share price return of 9.34% and a 1 year total shareholder...
SEHK:2696
SEHK:2696Biotechs

Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation As Shares Show Firm Recent Momentum

Why Shanghai Henlius Biotech Is On Investors’ Radar Shanghai Henlius Biotech (SEHK:2696) has recently caught investor attention, with the share price moving over the past week, month and past 3 months, prompting a closer look at its fundamentals and returns. See our latest analysis for Shanghai Henlius Biotech. At the current share price of HK$70.5, Henlius has shown firm momentum, with a 10.5% 90 day share price return and a very large 1 year total shareholder return. Together, these figures...
SEHK:9969
SEHK:9969Biotechs

Assessing InnoCare Pharma (SEHK:9969) Valuation As Its Autoimmune Pipeline Advances Through Key Trial Milestones

InnoCare Pharma (SEHK:9969) has drawn fresh attention after dosing the first patient in a Phase II/III trial of its TYK2 inhibitor soficitinib for chronic spontaneous urticaria, alongside progress across several other dermatology indications. See our latest analysis for InnoCare Pharma. Despite the steady stream of trial updates and the recent IND approval for ICP-538, InnoCare Pharma’s 90 day share price return decline of 14.51% contrasts with a 1 year total shareholder return of 91.23%,...
SEHK:1299
SEHK:1299Insurance

A Fresh Look At AIA Group (SEHK:1299) Valuation After Recent Share Price Moves

What recent performance data suggests about AIA Group (SEHK:1299) AIA Group (SEHK:1299) has drawn investor attention after a 1 day return of 2.55%, alongside a 1 year total return of 53.15% and a 3 year total return of 6.65%. See our latest analysis for AIA Group. That 2.55% 1 day share price return sits against a 7 day share price decline of 4.63% and a 90 day share price gain of 4.84%. The 1 year total shareholder return of 53.15% contrasts with a 5 year total shareholder return decline of...
SEHK:2586
SEHK:2586Software

Assessing Dmall’s (SEHK:2586) Valuation After A Strong Year Of Shareholder Returns

Why Dmall’s recent share performance is catching attention Dmall (SEHK:2586) has attracted fresh interest after a strong run in its share price, with returns of 9.9% over the past month and 11.8% over the past 3 months. See our latest analysis for Dmall. Zooming out, Dmall’s 20.64% year to date share price return and 41.07% total shareholder return over the past year point to building momentum around its HK$9.0 share price, as investors reassess its growth prospects and risks. If this kind of...
SEHK:9973
SEHK:9973Auto

Assessing Chery Automobile (SEHK:9973) Valuation As Shares Trade On A Low 8.5x P/E Multiple

Why Chery Automobile Is Drawing Investor Attention Now Chery Automobile (SEHK:9973) has caught investor interest recently, with the share price around HK$28.68 and short term returns mixed across the past week, month, and past 3 months. See our latest analysis for Chery Automobile. Stepping back from the daily moves, Chery Automobile’s share price return has been slightly positive over the past week but softer over the past quarter and year to date. This hints that earlier momentum has cooled...
SEHK:700
SEHK:700Interactive Media and Services

Is Tencent Holdings (SEHK:700) Pricing Reflect Long Term Value After Recent Share Price Slide

If you are wondering whether Tencent Holdings is attractively priced today or already reflects most of its potential, this article will walk you through how its current share price stacks up against several valuation checks. Tencent's share price last closed at HK$532.0, with a 2.8% decline over 7 days, a 13.8% decline over 30 days and a 14.6% decline year to date, while the 1 year return sits at 13.0% and the 3 year return at 45.8%, compared to a 19.6% decline over 5 years. Recent headlines...
SEHK:6682
SEHK:6682Software

Asian Stocks That Might Be Trading Below Their Estimated Value

As global markets navigate the complexities of AI disruption and economic shifts, Asian stocks have shown resilience, with indices like Japan's Nikkei 225 experiencing notable gains. In this environment, identifying undervalued stocks requires a keen eye for companies that demonstrate strong fundamentals and potential for growth amidst changing market conditions.
SEHK:992
SEHK:992Tech

Will Record Q3 Sales and Expanding AI Business Change Lenovo Group's (SEHK:992) Narrative

Lenovo Group recently reported third-quarter 2025/26 results showing record sales of US$22,204.33 million, alongside lower quarterly net income of US$545.54 million, while nine‑month profits edged higher year on year to US$1.39 billion. At the same time, Lenovo highlighted rapid growth in AI‑related revenue, restructured its Infrastructure Solutions Group for long-term AI opportunities, and launched new ThinkSmart–Huddly meeting solutions to deepen its presence in AI‑enabled...